Challenges and Future Trends in the Treatment of Psoriasis

被引:129
作者
Lee, Hyun-Ji [1 ]
Kim, Miri [1 ]
机构
[1] Catholic Univ Korea, Yeouido St Marys Hosp, Coll Med, Dept Dermatol, Seoul 07345, South Korea
关键词
psoriasis; treatment; future trends; SYSTEMIC TREATMENT; MODERATE; SAFETY; METHOTREXATE; MANAGEMENT; BIOLOGICS; DELIVERY; REGISTRY;
D O I
10.3390/ijms241713313
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Psoriasis is a chronic inflammatory skin disorder, and current treatments include topical therapies, phototherapy, systemic immune modulators, and biologics, aiming to alleviate symptoms and improve quality of life. However, challenges persist, such as adverse effects, treatment resistance, high costs, and variability in response among individuals. The future of psoriasis treatment shows promising emerging trends. New biologic agents targeting novel pathways, such as interleukin 23 inhibitors like mirikizumab, offer enhanced efficacy. Small molecule inhibitors like ROR gamma t inhibitors and ROCK2 inhibitors provide additional treatment options. Combination therapies, including biologics with methotrexate, may improve treatment response. Advancements in topical treatments utilizing microneedles and nanoparticle-based carriers can enhance drug delivery and improve therapeutic outcomes. Biomarkers and multi-omics technologies hold potential for personalized treatment approaches, thus aiding in diagnosis, predicting treatment response, and guiding therapeutic decisions. Collaboration among researchers, clinicians, and industry stakeholders is crucial to translating these scientific breakthroughs into clinical practice. By addressing current challenges and exploring these promising trends, we can optimize psoriasis management and improve the lives of those affected by this chronic condition.
引用
收藏
页数:12
相关论文
共 79 条
[1]   Design and optimization of topical methotrexate loaded niosomes for enhanced management of psoriasis: Application of Box-Behnken design, in-vitro evaluation and in-vivo skin deposition study [J].
Abdelbary, Aly A. ;
AbouGhaly, Mohamed H. H. .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 485 (1-2) :235-243
[2]   Spesolimab in the treatment of generalized pustular psoriasis: a critically appraised research paper [J].
Ali, Fatima ;
Smith, Catherine H. ;
Mahil, Satveer K. .
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188 (03) :328-329
[3]   Safety and Efficacy of Topical Calcineurin Inhibitors in the Treatment of Facial and Genital Psoriasis: A Systematic Review [J].
Amiri, Diva ;
Schwarz, Christopher Willy ;
Gether, Lise ;
Skov, Lone .
ACTA DERMATO-VENEREOLOGICA, 2023, 103
[4]   Real-world switching patterns and associated characteristics in patients with psoriasis treated with biologics in the United States [J].
Armstrong, April W. ;
Patel, Manish ;
Li, Chao ;
Garg, Vishvas ;
Mandava, Monika Rao ;
Wu, Jashin J. .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2023, 34 (01)
[5]   Pathophysiology, Clinical Presentation, and Treatment of Psoriasis A Review [J].
Armstrong, April W. ;
Read, Charlotte .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (19) :1945-1960
[6]   Comparison of Biologics and Oral Treatments for Plaque Psoriasis A Meta-analysis [J].
Armstrong, April W. ;
Puig, Luis ;
Joshi, Avani ;
Skup, Martha ;
Williams, David ;
Li, Junlong ;
Betts, Keith A. ;
Augustin, Matthias .
JAMA DERMATOLOGY, 2020, 156 (03) :258-269
[7]   Brodalumab for the treatment of plaque psoriasis: up-to-date [J].
Beck, Kristen M. ;
Koo, John .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (04) :287-292
[8]   Functionalized gold nanoparticles for topical delivery of methotrexate for the possible treatment of psoriasis [J].
Bessar, Hagar ;
Venditti, Iole ;
Benassi, Luisa ;
Vaschieri, Cristina ;
Azzoni, Paola ;
Pellacani, Giovanni ;
Magnoni, Cristina ;
Botti, Elisabetta ;
Casagrande, Viviana ;
Federici, Massimo ;
Costanzo, Antonio ;
Fontana, Laura ;
Testa, Giovanna ;
Mostafa, Fawzia Farag ;
Ibrahim, Samia Ali ;
Russo, Maria Vittoria ;
Fratoddi, Ilaria .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2016, 141 :141-147
[9]   Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1) [J].
Blauvelt, Andrew ;
Kimball, Alexa B. ;
Augustin, Matthias ;
Okubo, Yukari ;
Witte, Michael M. ;
Capriles, Claudia Rodriguez ;
Sontag, Angelina ;
Arora, Vipin ;
Osuntokun, Olawale ;
Strober, Bruce .
BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 (06) :866-877
[10]   Efficacy and Safety of Continuous Risankizumab Therapy vs Treatment Withdrawal in Patients With Moderate to Severe Plaque Psoriasis A Phase 3 Randomized Clinical Trial [J].
Blauvelt, Andrew ;
Leonardi, Craig L. ;
Gooderham, Melinda ;
Papp, Kim A. ;
Philipp, Sandra ;
Wu, Jashin J. ;
Igarashi, Atsuyuki ;
Flack, Mary ;
Geng, Ziqian ;
Wu, Tianshuang ;
Camez, Anne ;
Williams, David ;
Langley, Richard G. .
JAMA DERMATOLOGY, 2020, 156 (06) :649-658